|4Jun 2, 4:22 PM ET

Caissa Capital Management ltd. 4

4 · Avalo Therapeutics, Inc. · Filed Jun 2, 2023

Insider Transaction Report

Form 4
Period: 2023-05-31
Transactions
  • Purchase

    Common Stock

    2023-05-31$2.87/sh+844$2,4221,386,215 total(indirect: See Footnote (1))
Holdings
  • Common Stock

    182,300
Footnotes (2)
  • [F1]Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
  • [F2]These shares are directly owned by Mr. Golestaneh in his personal capacity.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT